Alnylam Pharmaceuticals: Why Its TTR Franchise Expansion Can Be A Game Changer! 

Alnylam Pharmaceuticals recently reported its first-quarter 2025 earnings, providing a comprehensive overview of the company’s financial performance, strategic initiatives, and future outlook. Here is a neutral analysis of the company’s investment case and key results. During the quarter, Alnylam achieved $469 million in net product revenues, a significant 28% growth year-over-year. This was primarily driven by a robust performance from its transthyretin-related amyloidosis (TTR) franchise, which saw a 36% increase in revenue compared to the same quarter in 2024. Particularly noteworthy was the 45% year-over-year growth in the U.S. TTR market. Although the expanded indication for AMVUTTRA in ATTR cardiomyopathy in the U.S. only launched in the final week of the quarter, the company expressed confidence in a robust second-half growth trajectory.